0001104659-23-089437.txt : 20230810 0001104659-23-089437.hdr.sgml : 20230810 20230810060029 ACCESSION NUMBER: 0001104659-23-089437 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230810 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230810 DATE AS OF CHANGE: 20230810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Liquidia Corp CENTRAL INDEX KEY: 0001819576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851710962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39724 FILM NUMBER: 231157020 BUSINESS ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919.328.4400 MAIL ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 8-K 1 tm2323188d1_8k.htm FORM 8-K
0001819576 false 0001819576 2023-08-10 2023-08-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 10, 2023

 

LIQUIDIA CORPORATION
(Exact name of registrant as specified in its charter)
     
Delaware 001-39724 85-1710962

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

     
419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
(Address of principal executive offices) (Zip Code)

  

Registrant’s telephone number, including area code: (919) 328-4400

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock LQDA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 10, 2023, Liquidia Corporation, a Delaware corporation, issued a press release announcing its financial results for the quarter ended June 30, 2023, and also provided a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.*

 

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

Exhibit
No.		   Exhibit
99.1   Press Release of Liquidia Corporation, dated August 10, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

August 10, 2023 Liquidia Corporation
   
  By: /s/ Michael Kaseta
    Name: Michael Kaseta
    Title: Chief Financial Officer

 

 

 

 EX-99.1 2 tm2323188d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update

 

MORRISVILLE, N.C., August 10, 2023 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update.

 

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “This quarter saw Liquidia significantly advance our mission to become the leading inhaled treprostinil provider for pulmonary hypertension patients. Achievements of note include: 1) the affirmation by the U.S. Court of Appeals for the Federal Circuit (CAFC) that all claims of the No. 9,593,066 (‘066 patent) are invalid or not infringed, 2) the filing of an amendment to add PH-ILD to the YUTREPIA label, and 3) the license of L606 from Pharmosa Biopharm to develop and commercialize a sustained-release liposomal formulation of treprostinil for twice-daily nebulization. With these achievements in mind, we we will continue to prepare for a potential launch of YUTREPIA in the near future, both for PAH and subsequently PH-ILD.”

 

Corporate Updates

 

Advanced litigation with United Therapeutics. With the decision of the CAFC issued in July with respect to the Hatch-Waxman litigation between Liquidia and United Therapeutics Corporation (UTHR), only one of the three patents originally asserted against Liquidia in Hatch-Waxman litigation, U.S. Patent No. 10,716,793 (‘793 Patent), remains gating to final approval for YUTREPIA. In July 2022, the Patent Trial and Appeal Board (PTAB) found the ‘793 Patent to be unpatentable due to the existence of prior art as cited in the inter partes review filed by Liquidia. The PTAB then re-affirmed that decision in February 2023, and UTHR appealed the decision to the CAFC. Briefing in the appeal should be completed in fourth quarter 2023 and oral arguments will be heard on the next available date in the oral argument calendar, expected to be late fourth quarter 2023 to early 2024. Once argued, the CAFC could rule within a few days, in the case of summary affirmance, or within a few months after oral argument if a full written opinion is issued. If affirmed by the CAFC, the PTAB’s decision would override any earlier finding of infringement, and Liquidia would immediately seek final regulatory approval for YUTREPIA.

 

Submitted amendment to add PH-ILD indication to tentatively approved new drug application (NDA) for YUTREPIA. The U.S. Food and Drug Administration (FDA) had previously confirmed that the additional PH-ILD indication would not require any new clinical efficacy data. If approved, YUTREPIA would be indicated for the treatment of both PAH and PH-ILD, though final approval of the PH-ILD indication cannot occur until the new clinical investigation exclusivity granted to Tyvaso® expires on March 31, 2024. Concurrent with this amendment, Liquidia also submitted a paragraph IV certification indicating that the patents listed for Tyvaso® in the FDA’s publication commonly known as the Orange Book are invalid and/or not infringed by YUTREPIA. All Orange Book patents previously asserted by United Therapeutics have already been found to be invalid or not-infringed as decided by U.S. District Court, confirmed on appeal, or by the PTAB, pending the appeal described above.

 

 

 

 

Expanded pipeline through partnership with Pharmosa Biopharm to develop L606 in North America. In June, Liquidia acquired an exclusive license to develop and commercialize L606, an inhaled, sustained-release, liposomal formulation of treprostinil currently being evaluated in a Phase 3 open-label clinical trial for the treatment of PAH and PH-ILD. L606 offers potential advantages of (a) less frequent dose administrations, (b) more consistent drug exposure over 24 hours, including sleeping hours, (c) improved tolerability via lower peak exposure, and (d) improved portability via a modern, next-gen nebulizer. Liquidia will be responsible for development, regulatory and commercial activities of L606 in North America, while Pharmosa will manufacture clinical and commercial supplies of L606 and support Liquidia’s effort to establishing a redundant global supply chain. Pending input from the FDA from a planned Type B meeting later this year, Liquidia intends to initiate a Phase 3 randomized, placebo-controlled study in 2024 to evaluate treatment of PH-LD patients with L606.

 

Second Quarter 2023 Financial Results

 

Cash totaled $88.2 million as of June 30, 2023, compared to $93.3 million as of December 31, 2022.

 

Revenue was $4.8 million for the three months ended June 30, 2023, compared to $3.9 million for the three months ended June 30, 2022. Revenue related primarily to the promotion agreement between Liquidia PAH and Sandoz Inc, sharing profit derived from the sale of Sandoz’s substitutable generic treprostinil injection (Treprostinil Injection) in the United States. The increase of $0.9 million was primarily due to favorable gross-to-net chargeback and rebate adjustments.

 

Cost of revenue was $0.7 million for both the three months ended June 30, 2023, and 2022. Cost of revenue related to the promotion agreement as noted above.

 

Research and development expenses were $17.7 million for the three months ended June 30, 2023, compared to $5.2 million for the three months ended June 30, 2022. The increase of $12.5 million or 239% was primarily due to a $10.0 million upfront payment owed to Pharmosa for the exclusive license in North America to develop and commercialize L606. Additionally, there was a $2.2 million increase in expenses related to our YUTREPIA program driven by higher manufacturing and supply costs.

 

General and administrative expenses were $9.2 million for the three months ended June 30, 2023, compared to $6.9 million for the three months ended June 30, 2022. The increase of $2.3 million or 33% was primarily due to a $1.3 million increase in consulting and personnel expenses in preparation for the potential commercialization of YUTREPIA, a $0.7 million increase in legal fees related to our ongoing YUTREPIA-related litigation, and a $0.6 million increase in stock-based compensation expense.

 

 

 

 

Total other expense, net was $0.7 million for the three months ended June 30, 2023, compared with $0.5 million for the three months ended June 30, 2022. Liquidia incurred an increase of $0.9 million in interest expense attributable to the higher borrowings under the Revenue Interest Financing Agreement with HealthCare Royalty Partners as compared to balances outstanding under the Amended and Restated Loan and Security Agreement with Silicon Valley Bank, and a $0.7 million increase in interest income attributable to higher money market yields.

 

Net loss for the three months ended June 30, 2023, was $23.5 million, or $0.36 per basic and diluted share, compared to a net loss of $9.4 million, or $0.15 per basic and diluted share, for the three months ended June 30, 2022.

 

About YUTREPIA™(treprostinil) inhalation powder

 

YUTREPIA is an investigational, inhaled dry powder formulation of treprostinil delivered through a convenient, low-resistance, palm-sized device. On November 5, 2021, the FDA issued a tentative approval for YUTREPIA, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. The FDA has confirmed that YUTREPIA may add the indication to treat pulmonary hypertension with interstitial lung disease (PH-ILD) without additional clinical studies. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape, and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA was previously referred to as LIQ861 in investigational studies.

 

About L606 (liposomal treprostinil) inhalation suspension

 

L606 is an investigational, liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer. The L606 suspension uses Pharmosa Biopharm’s proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period of time and reducing local irritation of the upper respiratory tract. L606 is currently being evaluated in an open-label study in the United States for treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with a planned pivotal study for the treatment of PH-ILD.

 

About Treprostinil Injection

 

Treprostinil Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration. Treprostinil Injection contains the same active ingredient, same strengths, same dosage form and same inactive ingredients as Remodulin® (treprostinil) and is offered to patients and physicians with the same level of service and support, but at a lower price than the branded drug. Liquidia PAH promotes the appropriate use of Treprostinil Injection for the treatment of PAH in the United States in partnership with its commercial partner, who holds the Abbreviated New Drug Application (ANDA) with the FDA.

 

 

 

 

About pulmonary arterial hypertension (PAH)

 

Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death. Currently, an estimated 45,000 patients are diagnosed and treated in the United States. There is currently no cure for PAH, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class, delay disease progression, and improve quality of life.

 

About pulmonary hypertension associated with interstitial lung disease (PH-ILD)

 

Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) includes a diverse collection of up to 150 different pulmonary diseases, including interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease related ILD, and chronic pulmonary fibrosis with emphysema (CPFE) among others. Any level of PH in ILD patients is associated with poor 3-year survival. A current estimate of PH-ILD prevalence in the United States is greater than 60,000 patients, though population growth in many of these underlying ILD diseases is not yet known due to factors including underdiagnosis and lack of approved treatments until March 2021, when inhaled treprostinil was first approved for this indication.

 

About Liquidia Corporation

 

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia Technologies is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America. Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

 

Tyvaso® is a registered trademarks of United Therapeutics Corporation.

 

 

 

 

Cautionary Statements Regarding Forward-Looking Statements

 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, including the potential for final FDA approval of the NDA for YUTREPIA, the timeline or outcome related to appeals arising from our patent litigation in the U.S. District Court for the District of Delaware or inter partes review proceedings conducted at the PTAB, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The favorable decisions of the PTAB in the IPR for the ’793 patent and of the Court and CAFC in the Hatch-Waxman litigation are not determinative of the outcome of any appeal of those decisions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, including the impact of the coronavirus (COVID-19) outbreak on our Company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact Information

 

Media & Investors:
Jason Adair
Chief Business Officer

919.328.4400
jason.adair@liquidia.com

 

 

 

 

Liquidia Corporation

Select Consolidated Balance Sheet Data

(in thousands)

 

   June 30,   December 31, 
   2023   2022 
Cash and cash equivalents  $88,196   $93,283 
Total assets  $121,597   $129,198 
Total liabilities  $60,940    38,776 
Accumulated deficit  $(385,858)   (350,596)
Total stockholders’ equity  $60,657    90,422 

 

Liquidia Corporation

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

 

         
   Three Months Ended June 30, 
   2023   2022 
Revenue  $4,786   $3,918 
Costs and expenses:          
Cost of revenue   671    731 
Research and development   17,695    5,219 
General and administrative   9,245    6,938 
Total costs and expenses   27,611    12,888 
Loss from operations   (22,825)   (8,970)
Other income (expense):          
Interest income   734    65 
Interest expense   (1,426)   (542)
Loss on extinguishment of debt   —    — 
Total other expense, net   (692)   (477)
Net loss and comprehensive loss  $(23,517)  $(9,447)
Net loss per common share, basic and diluted  $(0.36)  $(0.15)
Weighted average common shares outstanding, basic and diluted   64,788,482    62,179,305 

 

 

 

 EX-101.SCH 3 lqda-20230810.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lqda-20230810_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lqda-20230810_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2323188d1_ex99-1img001.jpg GRAPHIC begin 644 tm2323188d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 10, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 10, 2023
Entity File Number 001-39724
Entity Registrant Name LIQUIDIA CORPORATION
Entity Central Index Key 0001819576
Entity Tax Identification Number 85-1710962
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 419 Davis Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Morrisville
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27560
City Area Code 919
Local Phone Number 328-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol LQDA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 8 tm2323188d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001819576 2023-08-10 2023-08-10 iso4217:USD shares iso4217:USD shares 0001819576 false 8-K 2023-08-10 LIQUIDIA CORPORATION DE 001-39724 85-1710962 419 Davis Drive Suite 100 Morrisville NC 27560 919 328-4400 false false false false Common stock LQDA NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://liquidia.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2323188d1_8k.htm lqda-20230810.xsd lqda-20230810_lab.xml lqda-20230810_pre.xml tm2323188d1_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2323188d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2323188d1_8k.htm" ] }, "labelLink": { "local": [ "lqda-20230810_lab.xml" ] }, "presentationLink": { "local": [ "lqda-20230810_pre.xml" ] }, "schema": { "local": [ "lqda-20230810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lqda", "nsuri": "http://liquidia.com/20230810", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323188d1_8k.htm", "contextRef": "AsOf2023-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://liquidia.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2323188d1_8k.htm", "contextRef": "AsOf2023-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-089437-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-089437-xbrl.zip M4$L#!!0 ( XP"E='RJ0Q*@, .,+ 1 ;'%D82TR,#(S,#@Q,"YX M],_T'U:\8VADD3""23)DV&#DD:(&F:EXZP!=$@2T:2N?3K M*]F6N1@(T)8G>?>79GZQ30D8(RXP(PV+,\I60!1GP68#AK64\>^[%PU MFQ:X./_X :A?_9-M@QN,2% #U\RWF[3/SL ]#%$-W"**.)2,GX%G2&)M83>8 M( ZN6!@1))%RI)%JX-CQJCU@VSOH/B,:,/[4;N:Z;U)&HN:ZD\G$H6P,)XP/ MA>.S<#?!CH0R%KE::5K*?KO1[[#P<_(1O#R>G$S;^&6 Z&G<@I57_P<\^C;J M/02_7]M'MS^'4QE^F?6Z%)[,2KC[^97 #GL5-*@[C [=<*GGNRUVKD^"L%%B;$DR'Z^!>M5IU$Z^!%I#3'B=&NN)J M=P\*E"LK+]Z"QU1(2/TE?"!SPB+XV$V=2U"\%OHYA6(##= *3B#?&;"QJQP* M7ZX88"SL 811#NY#T4M$,\<26'!9!"KC*LB6LPB)M=#4M40@HP#F6()',0XP MU#.9H$JGGMXL@D)$Y0WCX37JPYBH1$8Q)+B/46 !"?D 23UD(H(^>D?-3"JD ME*F!5EN56;0MBK":V-R@3+K#-@/J8X"9UMD =LO2^Q+E,=$V;=7047E6*!@@=ZGIPCCH2B)R6UE"'C9Y#M M7!\2/R8'4>?Y;6-F=O,B"V_8+%(;]4&R@#4]*@U+8'T%6IGMC:-^P](C8YM^ M_E)E.VJ4#$1'V+* 28]6WU06V$A [A=4"A>$$F$1XA*K>5ZX!=+4L=3T[PMA M@(XC+.#^P\H)[.U;N:(@\A]+;FG]8JUU=WFSU//J]M55N8Q+0 MKO.T63>__ M%O,3J2T4_60;GJU-ME>V*YXS%<$\TWV2F+^!_9(PO .2V'"7KXLO-L'U(1FA M78-N^"9L#;J6XR(BA;$L3X"W[EXBD]BOAF M6(6+#&?;M*KMX^YC^:<(_T03]G2F_EKAE"!YO%AZMDN3\Y':;[G;UY,C+M:3 MXX\?IY-__G*]B![)!H\3IHY;1$8Z2M5BBYN>GIY.\E(M;2EW*T'U/DXFVDY5 MLRQ-.O0U)VEREN;VKGF$L[S;>W>#0(7ZWUC+QFK3>'H\/ID>[=)XI ]^?@0% MI^2>/*"\F6?9_EFBE":*A%&Y[5&0![L9*L1$Q4\86>.,Q&I'IVI'TW^H'?VE MW'R-5X2.D%)*/L!VG3;J*H,FKLW>$9'P^)*]S[49[>1.6 M/,/T7>;KD8;/5]31,6 FUC, DUK:>!_9ZL$S6U M* OJ_):HC1W#&*!W/?1WVC;G JLX"&B&. 1GBWH0JJ(\<73!V!;3>_+,11<^ M39EK:FPF35CJFJ 8L1@#T2BTJ!![(N+7K3QC)X+N>Z%H*5US 5@UT3!D0=%A M]P8"4LG],K(4F*6)&L!Z(6E+G9]N &9;IQZ&+BA. '/P*4FE]TO*XI%0JNX' M8-8_H-C$KFF!#9N\M)5!$0/: YG)(U 9$@XVER]J=2Z720,;6]/[A*=ENXN? M2APL0J;#@13E84C%>2*I=ANBAZ&6TC4]@%63&T,6%#%V;R KA1SE>O^07+)X M$"*5S@\@ADT['J4H0#B:SOK0D&J?8%PE:81IX>5*;DL[FF?1N@8$M&M"TA(& M!0KD#H2E"-#,Y"%>@?D7P6(8+C6E'UA:5NVH5+( 03&]]6&B]%X@F6V%:+B& M9QQ8ZNRF;(_9ZOXLH L"E!YSK;NVA;P!BJ<9Z))E2;97S]/=;# \EH-XM+#VVF\P XH#0Z78($"2#4#/*)TAS%G'QS&N/.\SX5@Z ^QF/ MX15*3Y1;J 8UH8E69TA @ WQ"6#6"/U0/)."N'J/)Z\ J1J\$'<1Q_) I>4_ MUPDC4[#]5JU;NCKL-IFR" ,B"78'\%,J/^@/2,6@6Q8*-,=O:.JQ?VB.AT)S M'#0TQ^^!9OG* X'FY U-/?$/S'2\M8'BPI0ZQD5XA.3?&%U*^X$?TE8!"^9(;D78 #35FH, M;7CHV WV\5,MB'6\'#:M@*24,9'BHV>WW %#%(!ODXL2YQ537N7@&V MV#J\ EPK# ("FZ/V*\#%U9-"Y+J;%:."8&!$:!8[ZV2+J:J/:V5A='';4*N' M\^^UU/CX(JOL+O3ND3/X 8&VQ%5/0^9T;YOE0?0X8,KL]5R&/>_$TDF=SSC&\V6U;>Y;$]-PCH7/5R MITW=XU91$+W?Y+9.,VDXNVQ)GQKR+W?1HS1%@!<2[#+70[_-I#G\US5!(-!A MK'524DJ1UOIX(>$P9:W[%P%K;XN =<\B8!WB(F ]=!&P]K8(T+LM4H3(<>EV M19,U!I(3=JI=0]%AV>3#(@T*%=@?.&94(>@0XSJC99[B3*7G%YM\_U?R@Z65 M@,Y93LLNFU522YLH"$:ZG+726A9)YVIBI-2NN=C&24;BPLQ5PC"+$DRK](BV M*^+](9#,X X")R&. 0>G5%!XR<5A718>27,"TG?.-VR M#(O\77)A&YD G5MR )M-8@Q10*38G0&$5&)4J/V\H%UDCZ@66<7O#H$-A.2. M7]?N-&V\M6W5!L1,IT'H'>XRY\=A;5Q$>7K%,B/J]R*2%_(%9[CT!K87DKM^ MJ;++M/DVI4T;$$*=!L'W)ZL8E2H&:Z:\I8P1,[G46O..I\0-E?O$,2V+[=PQ ME20@/&R^.C+("*2U7EA8;#"EG[=IPD@*3T2&RBT+5HM-%AJ2@%BP^0)8R*5( M:[VP<+DA8BVGMY\$?\T>R_RL8-L M5LV.BTW&;%* V*ERQ_ C Y!18Q.J>L' MGMTAH7B191%NJ47J&!O0K,%,2Q<2,)"Y%BV41.IZRPW/T)*CKRE!V2-!E^7/ MT-4SP1?U^/JED2A2+T04JW(68V%#J$OL_%='0,.MWQYI*8, J=<>_#LD5032 M(8ZIN94,B_IY7&YBGI$-^+9#?X@K@H::UQSUZ8.@::!)DZD\K'ERG0DS MFU$]N3V\Q&N('*^,+0:-A7%-$00CH"UH65S_K0 _N?.V*YI$5Y1C^"I+0^,X M8U[;GI$L[R (B("V*RA%7BY$N=)+_W_&[$ELG[-H?R=X1(AZRBJM1JN^ZV\# MH]TR\Z8F-6D:%!H09V_Q"Q!XJ +5ZOA0F[%\7LQ3#XVK;&X\>EH\8GD ;[=9 MJF90:0R^"MX9Y/CVPH &&#<9.B("0F^ 3>B&0QZ)\M /J A&M6A/YV?I(0L@ MB3_O[\D#$>J]@R7999_ECIXZSC &Q+H^>QO<'/-DKCYZ@541'+A(GI1>O+J'TYZ@^' MK4@;(A+"I: 7+2%;[_[Z]9?(_IS_UFY' T9YJ>G MI]W\VU)ZH%R.%2_;..F6W=G4;+]E ?U63S0[TWGW;F1,3![VVF8BK\+]URYE M;;>IW3MNG_0Z2YVT2O@Y024YO:>3R/VUT=NTRMF/C"6,N(!UW9?=OK0[I.UI M7FRFZ.2BQ7\DQ-9^?'+TIG?DZOY]1V16<[MC:N;VJU;4W6EWKJBFPN16;^R& MG2)T:>SN1).R(M<^M&>&&2=>[RR]J.WVK"RU;=F/A7+=D;(K7,8[K7,7 ;EG MM=R;<\Z:QIVI?.HFE'6=??QWZ?MH%VJ.)(JH&.N59TYT39BMKQC/%- ME"=*ICXZ:Q+2T]%M4+:)9FA>VO83UX!M!*-UA$WU,=*S9W M7&K [BB!?(]1^59X:QAS>>S$1"/II1SET*1P1H+Z_2 ['_B8G=[_,%@+]^VJ! ML]\J L3_YJ7@/W"+%($[JIA,["E= =@?B('43S&I>QRB\KX6"93V1@K.?_!A M[]E#0CU@.B:\Z-' ;M-AW!5R*'*4G+/6)BKV?RE18.A;8BARE#2TQF+#P/N9 M4CN="8XJ?C44.4H"6F>R8>;7PC"S-TUW6ARHH8Y2DTV<*A6UY MIT$8]R@CQ'=?"66,DFN&S*%P[EL_BO"A2.CR(UV%0!](H:11_[EA@O9"H:B4@Y\1 MX04@8/.%8#]^'O9C.':4/+36Y@O!?O(\["=P["BY:*U-3.Q]^_%6/K-XI+?JAU1M5S^5>4@D8!)>V#FFYZG*%Q9H>]5>]X_.!6S'A&F0,5E#5* MRN_THQKOG@0*%B6SJ[2# M-"9<+^,9$5/JG[U0K80"1LGT0N;0QMXI:.R=/G/L1:G&>KZS)[H>V+(NHAIG'. MK5LK^8.GUAT=E#=B8EIE#&?-5#;F+!YP28+7Y3LR*%_$++3"%@K>*R(>538W M\>I.R9A2]_A$;XXV0$($K :$L3\]%DH<&X7R#1UBXED_#B:6=/Z-C/YVTMM M_X(W#8+EH*'!7,0),(YT%:1_+O2BR=7JGDZHXNW/2MZ$? M]-6M;[&^;9N%9'(T&B5&Z83!>DDIG\\GQ[Q/S.U4&(?VDU,I*?GK^JJE],D MQZENV5A7R'201O7G:/B\==JUPS0:Z,J?^$C2R070T*K.!LQW/DRZC8&N=FC7 MK-O5]KM2R\C(TM%;=+@]I@/&47TE3C/,D/PZ;5[-NMOA_6==DS;#NM4UV #; ML(8<4C:>DN/RX1R0N$64 "#XG>@9PZ5PXN60'?% M<'2;3<(I]AH# RQF+X*&AX%.VHN*I[TT^N)0E>*$8@Q$KU1.2L6$))T/Z%U0&R,.(PX 0##;[&RH=M$M^/MB0G<5MQ?WV(V&=M)5P>3 M?%S2 WORCW@E4@,^ M.'DH'E]U=#K]R*?Z.#_%1W^*[X"3D:>CUAF>S3X2D"Z@'_Y6=>#@I RL85BK MZ2H97Y+)8PHL4$[*9X\.WP,W/P>W-""Z"O_;9QKN/7:Q9I%W@#H\!3Y7'J5' MSS"X,.'1>V#(CZT^9L1ZE!^%'72!6.+9>^!4."T-#U9Z@:1(X!U#G2#+GFCD M6ZP+XE= 4LJT49L.H,L-&:&F,<#Z@?O@ A@M"L$7:5#?YQ*+5/#DP+2#9V( M1CHN<(DEC*N"^$55E>A",?A/Z'CC# "6XLK\V&YRRU&RZETN*]Q8@3XA'68* MX DMA$I K#@3@9-D .SZF (R$2L*H0@%G@Q,B^,"^T88N%QBN3VX&2U8PC\" M4B2<7J$O;"17L;BO%HFQI<:\9AL,P;>810>F1ESE]U %@;OH+,-A/C;H)M:X MX$T3475AFKYA\KL2P=7IT^ESJO*6+B4,"?))J,,IURZ#*_!Z\ Q=,A2?A\T$ MGAKJ(A7@]9E=P38ISJ;@0YJU+0R#Y8L8Y+>\)BM @/_08V.0MXY.7<:"2BUP M1(%!X31*>U<4&Y8QD7>\K%" M";!ML+GF]_/@-8UA4.>05HAN#*B^#.UROKS&&P;8;P]P88&AGE;.Z:!K$GR[ M=Y*$\?#)_SLQ?5LYP*Q']0("9?S7/Z7#U/%)TBQ&=IDVSOF IJ.1> /WA*N: M-\/NN+AMF##6!$?A/>@8MFT,O&165Z]?7M5:K5K_Y'#KNL-6']- V8'PE44X@.97-Y#>*^_/6 M\:S>O$8GEHEU8=YX7)1/Y42X%X]7#,7A7IT'VH_*-#*=Q:A_E:NMTL.1^GRA MYP#<.J'#/(Y8,1>_?!TWG"0Y=<7?E+\@LLWJ31LUJXUZL_TY MIPF.5@W4:V M 0,5GLXB*8T,AJ3LGKJ/C"ZR^X0W.8S:E%B[.]6QTL MI;;PL&^(DO?55OD_; ,KL2JG5TB^]ZIC#*:-SYGK/IO.%6$+6291>/*E(@I+ M85L(C"&8 K;_T3E%SF,JM.G,'S,UL=7WC4UO;NQ&9[?V*H7HPU% 'VJZ8C"P MTZ)&V[+!VI7=VF394"/40SG[F;V\(O=/['WJ,6>%>?F89\\V,9DQY#(4-,,K MT 9NB&AX! 9\117Z9#8'SE(2N4/ MY>W9Y_E2P':"A3VA,SQ,-2 \9>@)HE-+I2)^=4.(+1, ?H'.Z_ ^QQJ4M4_@ M0MD8#*AE?=:DN0HB5Y#^GOG6FBU4'9B:,2'L4V82559<2RO(\KJA,IW-XQZ71X?I%N#BKT0_8N!&&LF)'R MJ(*'U$(51H=1WO1@H:9QM&0N9C<\%SE6;#D4#![D+2O/ MXBQL%F7X6F=M8Z2'SZ'$JIWN=4H=3#Z6("R@BQ6O#09&>D@U;?65R(;-0=C^ M.FM ? 4V."*4NTNUC\8L.[P?;CF4"RQQ*[9QSYL43QU-!K) M3:PA,B:*8X,1@L?@3HBU_UG+O@=\19RQH1EJ4M19BANLDWY*G6Y6?_C7/W.R M='1L03>-F'U#)T@7$*=G<@E\*P[BHI(%"#O==Z<.KI 3=7)>@: M+?FCGY+U7.]UY.JZ_FH>1ZR8E_(1DKX?Z9:N#!#O!I_J6YG$Z16[+]\/U/KS MFH2^1A,KIN57%5_&Z"^8-$R"2U:A(=F171.=,+ :]5T .&(K'IWIY20$R[=^X6ON[L6(JSQ+AY0;5) M=S!EKH76NSHMUG7N&+5A>7CV[>A>;FA%5!25G]?9P_[E WG?IN?\OD[',#2" M=7%2:MY AY+A,C1W'&FCYS]0-!N6J+:'>W='"6!'YMQ^(C^%@#)RUA/ X#ZB MV#W__@J+W,MD5J@:(O*%AI$L_L*:L) MEM=WXX(5C#*?',NFW;5+Z2('4RWJS)/5F!NDU>K.):HX\WOH%N,$PQX5:DT''T/:6E.=^ M U[DUN?%C7?P10@&\4T$\H4[W6K_Z*)QI)2U"V7-PMUK/+$B][0&GXFA/"]+#-^0][]%I#>V M#/Y)94_574T/7X/<2]4DA]7&S_RZ.WD!)+'BU6VE]/LQO@T>?2"T$:P]1-0?= M0SUFC&R(,(R!R6N0V$(JZ5+=/4'IUHA2V<6#YCR6W-UQSY>GT1YGQM&Q*!3Y MO:DX?&GRPY>\NNP&Z7(G+H< "SNT/@7* _;9N#FPB:^;$'K+1'5^0@6>);)4 M?RM)7**O56^U=G>"R^53[4KZ.BFH%-AC]O&<"RQE%TE$Z;1^EAVG&OGNQ8>S M3YLY9''W.906L5!R:FG]=*O+^ E;$VM+2JV[NQ.MWGS7-=16T(5MB3Y8 J)! M%@F60#=$3NE81/0":L7N!Q(O6J BSW0OD?+5%:FZJ4TX]A$%W-RLZ$ O& %& MAM2"@6!@L*[P2B-6Q"L)>&?^F@L5,]5R]SW4J(PVO8>G&>V\X4BLJPWO5)G@ M =OJN#WE@GMY(UQ?6E?IN^RX>W5U\[Z#MJOKRP(AJRK+UR^N_9WW0)<%='/W M1#=W#_1K\Y[3? S]7QQ>GP.P[@1$=+S(R\CX=WZE)#EDJ0XY$T,NQ\[SUBSZ M-XT7T#."G^,= AH$-)J"YGF4AR$8.1GO13F_I-M=S<\YP,!3G'>6">8%/ZA? M876.U7Q94)W$ IQTBC6;#)"<2,E+S^9%T93?.$U-8CF:+8Z4U4W"O HU.#,0 M"]_/E0UPO+PA$7%&CM^H_X+9R11@74?N9407LG\C\0!=>6_*@2E.S]L?((S\ M6S)H[AS^P>X.Y5L)*K2;XA@>@Q@#0UR!=1WB $6C$)2@])8@S'FN6,0LC\)0&@AR37\1,[.Z4X*$Y/701I :2C*[# M=&KU833D4,0-9'BBTJ<=ZO$@GT](B7__S@7UI>H>>6+IDS4^GTA)7TCC9WHM M#A;S'2I7X3WYL'Y7+=]3]_\WY7G95>%1G]HDSNDF_$5/(X;-*>;08OY'Q,N3 MHI,.$Z] NC$6Q.D]%T3E)7=+WW]+>HN:Y4\]4GUL-IM!\00C]X52]D!.RVDI MEU.E1S+.Y^-2HF\/-DD;-_93BO#KRU6AEX0^D;H )+%@*E$\IUMPM\3YZQ'% MQCKXN:;GY\#YA;MO[B/5UP[?G1EWLHG7N2-^:YG>C"4WQP,IE7E31:)LP5NZ ML662RP8@$.F42T2-:Q=6Q$V$"K8Q$G?Z]LB@0U0>R/ PA.HB8*F)]UTB_L)+ MI'HOC]A/_(8NY]^(;V10??K"3EYXGH;YTZ(O/X7KXN9'<:T^UC11E^H0I!+P MP.KN#K]L(*>.N\ S57R7CD78:#H@V181 ;I71?)D.K=B+?J QWYXX,:<>WR MAVN^LX=R'_3$O_DZHJ!DEM-Y JR\AL5':A1WJ.;B$M@Q6%J7J@.8$?/F1N>F M-G>9%7YT)FCZ-CS.*UY?\PX:AQWEA$AW.I'T_$0.D+%X3N: ;RD34[Q,@8Q% M5,S/-!.;G'D)R8IOASH(*_VK#JB]@AU>K1?V MU[WWP?& 6;* W=!@N.]8Z1"P6%UN&C@@P5ZO T^='1W&"'#8L?L& _>G;M$^ M?($D(U@CVV"X$%: "0]YYBY1;A!_6*P8%:6OR)S0X&N>^L6;]A\%OT&&G$X* MJQP0B4BM-KDT22N)KBDH-]'0)83V-O[8POB]/+G/II8DD7Z_U;IELAO-&]U7 M0D=/WW^%Z6;$9\LR)0Z%%5"Y3TEWKH!<%Q>3V5O3VF*8_T:HE#Y&=5.4O OH MBM\0_#*1TQ;#F*WY+WY(B;^47)Q6XJ_ +Z[X"O3O"\Y>G4XNQF=/ M:O5R]%2Z;G;RO>2X9'$:NKV M=E)ZOOE3);76 VVWAFKM^L;\09JW][8E36CUQUVY_N3@2G)2Z73.&B,K=_EB MW\N_%*MQ5'JJ3"KZ\V P4?5N/YYPM9?KQ\ &R] 6 =&TR,S(S,3@X M9#%?97@Y.2TQ+FAT;>U=Z5/;R+;_3A7_0S]J;@JJA(-M-B>YU#-+;CS%) R0 MF9I/K]I2V]9$EC1:<'S_^O<[I[NUV(8 @1D3F)JJV$9JG3[[UD?O/ES^_R].3@W6O]+_[ZVOSYW>&GXS_$Q>4?IR?_7AM$8?9& M-+?B3%SZ8Y6*CVHBSJ.Q#!W]@R,N5.(/UG C;CVS]XUE,O3#-V)K[>!5V$_C MM^]>G\U].SPX^3KR^WXF.IU&\]WKPX/Y)>[X M%%>%F4KL8S:S*,:MQ==^E&716#^\]\M_Q,7Y$6X?M]JM=G-_WVO^G_K:Z6PV M_?%P:ZO9^#,>KHGNZ>6_U];N!YC![/:W,%O!"BX%N'WI?ADF41YZFVX41,D; M,1GYF0(8[S]]O*PNOYGZ_U6:>HS04_^OW/=\N;IR%"5QE,C,CT)QKO Q2_$T M-PH]\6LN$V!)M+9:;?'>#V7H^C+ 56D>X"J)2\Z2Z,KW +)=1HG/L8=_-)4( MC 4XN2TKS6SXFQB\^X+SB!K(L1],WWQKG45(_>73^7GOXK?>Z>F)L[KRL7'4 M<$0W'^9IIN%N;CF,2[N+ D.;^A=+%%&ER?K'[L5Q]]J[DCYE8O]->TO(QKBA[SVY!!S"\U,W3U-^V (X MB'%BS3A8S"TX)V?.:2PSOQPG9J/GT1"H^UD-!KC6TN15DOZ51V\A#2-?#<3) M5^7FF7^EQ*?!P'=5 JY(I>^]$:\"CRZ\'/EI08943HJ%1 HMY>,>&6;!5$CO M"CA4(LH3,?;3E/@":.Z#CF/%6 Z4]/QP*/QP) -0,P,?)""6'_J!Q75"#+"Z M$N?!. IE,A6C::SPZ)#7B\%N4(II0W1=0'^EQO1-1 ,11J"-'[I![A&W;_ # M)7:4C#6+]J?\T^?&10/LDB<9W=6-8R6#DNG>*T! 7'#D)VX.7;Y^U'U_1(N! MBR1XRPVD/^8'TN4?(X/HCK/3:3M;N[MB_57 Z*7/@!;@;0B9$&A7T.H>"01 MQ==! E0H#UR\85@P(-Q@91FNKDALS*/-$0JE!QWV8;-W>DS?Z.(_/E^>GYSU MNB*0?14XS*QMO4X &H:IHH5.=[=VQ2")QN)L))-QE$IQZ$!1BMAHDI&QN0$,&QZ M$BI*A*J?8TV^N"%^][,108GE9)6 ?@B6"8&,B>+_(<:K*Y!_K)DK@C7&,PB- MM+P4<42()34?R#QT1P1%@1*L17@(E00OY5F>*$? 5H[XWK/N!]YOFO=3]5>N MF',U;ANO$N;W999LZ.]9&Y8N=C66".:'M%Y=K62\U97 S_RAYL$)<=7GT">+ M FN0R%A!H[G0$A7S95D/;._ZJ65=LAV0< %]E>-N\,[/>3#5..!E80YBY696 M\#[(S!UM_BZ_ EY1@K"ZTE?91*FP5([$90M@JIO-SY4#;Q-V*> =&R:*C:<<@CAA'$K'@?(J[!5\>-HI7?&RY4Z"X9^K[GK M['7:A=*BS_HR )6H,3U#T")03$ 6&N&Y36Q*R660)"A;"ZN]5/X%Q+#?>UNJ82$NX4MK451AO=<7 3IS7 M$(<)S+ VB]IH:?RDHR@//-HZ=',<*+.9 9FN46&/V>NEQX&E@-YDF&N%RHX0 M[ATIPG)D5>)78.8*>IFPN+I"ZL,^M7:_< %TZ,G$ 7Z)_6D'3(: ;ED$ _Z, M1X%%\6V[(3X116@YLG"%E+F\I20/5"EA/ED[,0 =X!E"^ T\KM0V+,W'8W(# MC"G'L@[94'VGT#?"4\A&\-@&!$U](_Z KLF!C$GB9V 4$<6P4T2ZU @]6'<@ M+'TAR-,"7@TY\4'A,Q64G_!6HBN5).PAPOFD_?ODP,"2&5-NS3S!HMFB$%B] M@ ^SBV^9 N92I;YH&2,O=$@6-J*=+Y2WY=7X=XKX[F<*;GK$X<%%WA\3K;WK MW2BBD*MU,,DBZ15R@0.+;?![2!R9Y$/Z); 7KW^D\*:N^*I!9'5_UX)X2?J( M5?+[*/*8*X[I05T//A"TF34.[^E9(TEA"!15E*< #SY151&QOO \GVX A\SO M3G,9>9P)W!T_T9Q*>W/A;N(J\)HBOU^Z4PA@)K4T&"0XI5B73Z-W%Y[.#5Q I,#E])*4&5*2D M%W^1B3LR(643H8]67T=1B$)]AN@+@IF]FE J"\7$J M@H"]:Y/)AL&H;U+:CHB5UL05L^JIU$W\/CVE#Q9O/(7TCUWJ?S8WQ7M?!8C- MS^10O<7U%,*XI!7%YJ9)E;X[!N?5\GHZ<]ALQ=E<\G"7E6F4(.PM?CL,H+E$ M$P]/(] ' ,SG"N>#Q?5#^RV9?@:T!8\PP5T':70 1@7G71U80 M\YHPHY&QI-1\R'#HY&LL*3$&Z?1C!=7(L0,K6_)S0Y6D(S_6.NS&' "G"J!A M/D;DV77'>*0K:[:-_?M0576?RQ:%E$FA?Q4%'CH!<6.&@9Y'#I'-!3EB+N'@ MW#+C8!1U0!J&A%U!J^22S3][B-@WH&G#\5/A)N=+2B.2<52RT)#5;5A#8R@: M#(#22OZ!DUX96(YS0NMR0_-+H-)4#!*=88"C'5'"HV;>0=?UOKEZ#/$@A99R M*)-IMP,V*DIS_(%\3-':%K"A"?O'E..BC::!4C%],']9=\UZ_MCX,%D40!OW M?<2"T]65*] LB"84 T$LBP=HOW3=F[V94K3F7D&W2OC94!/@2XHC-H?0YB:Y MHY)&Q:\UD0<%SK0EBM<(P887V'[6_=L:_'"$F-YQ&L?]B$_VBSK%IO$)Y^@'#CQHB!:PVK*S?7DIY$M>@? MCKX^'QS)=$0NZ^>[!459E'&BY*?]_49+ *R =+UD29VO^CB<%)&)]O)_ZK0; M[9E[CI6KQGV5U%W[UO+[>_\X <^AJ,-2D6RGYJ5:ZO\2KD#1"B6Y6*5I!'" MRZ#$&"[2+10ZAV*!+A,95=$I\BR6WQT2EHI%HLQ*^?1 #2F)HN;E)0J'$0%E MU]FT?Z\6IYG0M/SNPKVE6>1^V>SC&\LW[<>F_'EORR]3M\O@MEXRN,\L@WNS M(KRD@!B.)!DLR^N4>LONX4@LMKG!""$OMW%?]5=)9G+?U= [XFMC% M#SGME:BT\*.$S++$[^M JNBD,-878I!$$VB<5 +2D-F@\&>73?%Y"BG5671N**F8@+X,J!=0: "Q^>#O;]&YP5-16',OQ2T8]["_5C@2#\ M2(V6<_BQGDD48DFP\A<$>E,2M1=WQ-11/A]\5(C9 D3"5>&ZHY2PE+7:I6QP M/1)T:^^21<9.4H3\'![X04[\0+D$57($"DM#I[$]NUQSY^;E[B:1 M3Y/VAP?=/B2O<"Q>P47TU-OU:D)E0]>63']>'$T@F\O=*WG#CLONUE1KS$KS M U6^;4NUETSM7F\LFGDJ@$?-3&?JA=3CCE5#GQL<@F@"9XT*4KKE*I;!F(6& M@UN$8]3BA6#LJI)DW6&6:CJVU@$O47=5RK+#9G$W$Q=TW!'W9-W<7E+VA7.F MGCS76H/X^EGWPP;72'09"V:#O-H4JM#6LJ@HZ,%;GBES$(G^B)(O9 623'33 M-((W;+I^_OC0W1#O\] UC39'@4Q3O>M>;[/7ZXET.H[A_9AL'%5Z1FPR:NTZ M=K^K*V,YY7ZD;%1TU-AF)-JNN*;_G2%EC4_91&Z SF''/&R0S,&Z+E9N\'4D M'Y7>H*(D1K4@G]*&)303[KB@=GY BI ;2\[5PL[.>Q\OYSII,N6.0G#J<&II MJ$*R/*GI>"SS(" >US6I+NV[^@IJJD\H Z4,B:#-\M GQF77'_SFD%J+39&2 M-&64^F7<4"RA0HB18H8FOE$0!VH3!@3V!IL\980-HB!@1T&W"Y:*HO105E=& MQN;KWLO>QXNSWOD):^%>K??(]#%=R('*=#F34QG29;QP,0)T/--"V2L>17^H M)GJY'%X6J1TQII!N4Q\"@U";2E^-CM/9SO>"I[QA1T*2+_]T/H$_$N KE M*S\?!V^OE"XF+CB,01V6YFIHUE!CD%T<3G1?TU:U;NO!]=4V&I4V,EEK($K4 M0"76]*7BM/?K_FY3>S4U!5MG6<+VY2O,TUC+_9$V6+MTO M-E<+.SLX:UYC0YO_T8:J5I2CW22;7JYR6K8O@15?"_:$T@I,T E8J'H ML,VYKABK\"!Q210GOLI("R]N1:%">NC*.,T#4TLO8=?:T,7NN1F"6UK@HT'M M4.-4%:GA"Y.:2M^ M=PO.::S%-E :RUS$H[>TAY6NB]B_HNC:P+VX_4>W_3Q)R2OTS>(ZXI/5*(NW M0\RJ#]"!":B22>%0X1A^@?A0=\,N2MJK$L$]*,?SMW/68=S-8[@KOKA MO+FMFP]:R4]UBYJVJ(4SP,7 >#1%Q.C#FMN>9@-W0%X:G[50";GVHM(3Y8A^ MGFEU95K'$KH"?I<6]G["_8?LVC7JI7-=5S2>(+O]N!=BN[J2ZU3/-8B]MAMO MH7YAGV>FT]'/TFK3E_F[PR[-* J\5!\)ZO;[Y(EPL$&\J9OPJ]W^76[W+[ % MKWZ)%<+MTLSMES3SDT@SWT:]?\.4KJZP+7VRZO[L5IZ"GU)I+-&9M%&",,5U M='U6I5P\MLZ *_-4GRB F^>IT%;+\(3$Q(+:-9I%JPU5R9>C(^RD6GD ")^N MR\0 +BG\,AV^4K(YR_FPI@?]-6J((^M(<8!'?O"85<[VCK.UM551THFJ1&T< MW9(&+,XPUA4?N[1TH*/JJ841?5&Z7PK8@;W1'N4PHE/NV!\?E^0C$5:[Z@=3 M_ 5/E+5AD? %'MB 4M1P+1[81S?#&Z@QPZ/<)(DL M14>N#5ORF-BTN;.%O[.3$U:)8!:K= MGP!1N ZZA^I\--'VP87#I$:%K)Z MH5 Y95C#*1@ZXNLJCN86N%6I&++V2;2OM[M54U;%D;XXBFTP# Z9,+M3$\S4 M*--4Z4I<,"5ZT*,MG>@1=/QLJC)]9 UAKFU.=!&0IA4Z\A)&-_IZ- N['E%Y M5+&JT/2)PGR@4;=)L.#A@:1R]Z$.5E?373/-J(5:1=PEI>[>MK) M=<:# C5=\J\<.V;+34'-XAS\99&#UWDN"V,44R*,O1==XJ$ELDE$<1#Y)Y Y MI2>AT/;)SW$JV>]B5?K=E#I"MU$_Q,X^QNGI427TJ]['-1"#&SQJIEHW&\"6 M^4]15K"X8^_1,DBW+:@T5E<6;Y#8A(X FTURY:0\VE;/8=_N.-N-.4]R=6^; M]-25X'Q!V^1\H*['HV6:>68XE],C-2G@U*AFY04%*X,[.M'GCBB#89,NB^-] M.@5/W0E\.)D08]K"8CUUZ,J'21;O/A],)I-&8 =T ,I*I7Z)]?+:P36U$M8O M^%Y0FD2"NC-8V!<\6W2$-LO:8@?( UQ)'/6;9!Z]ANU^W6NA@BP M215"LB?XN'D:15^XD%%>]60=#QZ'%U. :ZLZ@HKY)GHA;SH\-CLWY'C73QB75R8%4:FQ5\]5$W96(I;1S@8[*V1YBX&* MHBS8XT;.A6/-H6E=*B\S9UH18J5\I>A3'P)MP=RA*^M4P=%/X/[B_I\Z+--U M)@-5"8HCS,RX*DDJNX)9OR C=?T5W\1&_2@YQ8HS?18:6,9^\:<)]9FL%RMK M'V>0%\,J$B(X^1!0_'ZLC[#IR$NHD$J&8U-=X(X#&MOBF%J6_JR/MYUJ+H^?"*!YWS9H]CP+JI.IZXCZOB61YSHF8[$:K:JP 5'&CM00U2] MLYPIPY-?J"MF=OK+1SH376L%XMR\79=@-ONH-I=+,[<17BMWJW!7 G&$'E)2 MZ2\ODF?5*2)F *2M-!0_\[G10$Z(:\CUO&%H&';A*N5QKRD='LYY2):9ZJ*G MCW!O3YKFTDXG,P-4["3*B[/+3P4KV^XD*BGS1$Y%L<6,R!A,+I 8^)I1<*6J M(SD%T6:S5 K'<"^?12 M._^TE$+'3(BT?^F#1>'WVY]AW,T?[.3*V1L8S;,_VO3,W.\\>6WV5ST&8/97 M6*#9GTA3SD-6B.7G3NVDGU4C-P ?HHD-S6 M;C+%J9E.9#H:J"_)(T 'TYO4M_A=Z1E#^GB(SC==?[T("$ >M0B#"*$K,F2, MZHK:,]O6WSEY8FP+I_=G31R5=SU3))@ &,T6[!9(2!0IEKPJN:0OM$TLQPW7 M3*@S;_T<$_<1;^L$6!0.];?BVAD;7+&.=7A#*"[-Z?/HJCDL1!-H_C_- $PI MPIS:/?DP*2L7,T-9NQUZDP&KQ*)F>G%R-&L:H#ND5K8ZX$S@05[Y29Z*]:-/ MO_6.-YN=#:)/QNZX48/%B&>K,!>@TUBLA0A%'#I1\)GXX%^YC06:$1I['/-= M< ]^021 _38\F=8D5+B#5.#'J3Z01(F#*]-V(V/?TW- J"%Q"'.-G45AD1@B MR'U8"Y!URMD1/QSI3#8CM,'^J<8M:)!0EP!4L+:''&SCWX;H939["N^J'+'" MDY=E*/6\03,VEZ2:1Q?SJ@[N2KB2A?W0^"XS +ND"5UJ,[ &]9;!0!1[,M-. MYM1=3IP1XWNX/1)8Z;/^U>D-LYK# L%5N%GSP].XK[<]=>\6#^/L['5"/M&2 M-Y9?%$\E#;A45Z2C#1IN)+RVW761K[%ZZ6&3!)=10#FU[@Y&5I]TY(I'?=M5 M_Z]BW(ZIEKE(^@ZW2OMAZ93935QPF+F76I M+2?:23]FDK-G#IU/3,H_ P&H(NGEVJW1@].9H4PY,JG^#)0%&3>VW:3R.8NO M\Z,:8$(MS_^&W%3S1]3_4R4?B0?=-_'3IUMX/"(Y@)CVRHT^:!Q]P].?8F:? MWG9 TU4U[*_D.(;_H7NWH8_>O#L\Y_>(%%-]?I;$YUU/^HG^FYZ0?VCMJQF0 M_W<@H=/L--JM_<;V]M:6@?/SP9\$7T,2?/\[GPI=5I:^74)PYR4A^"02@K47 MLSQB)9&GML-*,\A3E+'[DY W'Q MZ8DX.CD]/>L>'_<^_N??:UMK_/WBK'MDOUMNU&Q.71$R3L&0]M-;V&(O&Q% M6__2BO"V+T&B-RN=VP=U]1R5=7:;5T>'\Q<1JO MU[@--)5%RB<>?2)4?/SW6FOM7LN^%?.O5%H[J)V$?#BPG\3>YT:C/>#^7U^> M+Q53O872]BCR+-7SS,J/B^UOVR8Z/#R[Q04P6ZG^.[GR22"O]=C(NS5++W+G MDF%_O;6U[;3:^TYK9V=C =L;U;W7NH/FKF,K4 .0A08OZN83^D#3WKG%BTIM M=029!][E>=<0O;Y@\SLW\-,U@#;O8M/J"W.;[MK!_K[3[.Q>M_QW@KU8T)X? MDCMMI[4_I\H> 5FZVFL]/9 M>Y@U;Q*@'P]Q'2BA_<="W&-;J>^7C\#7-4Y?_?!"LKOE=+:WGH.,?!]<"Y$' M'MS;FS/62R$GCV$\NJZ;V<+YO=!I6/CJ1@0G@1)YW=5DIK&$0YSLNGRT?[![\F#*G^) M>%#ER?R@RJ5)\"XSQ5YJ%D\(><^R9K%FWRSTDBK?=O;V7\H1CXOCMM-ISF48 MGD,U@E[WHQUL^_:'-_=SD!9??+>H[=H;#97N<><='OG4-[8\.1EKH A&;GO3 M?%9YK=2SR"7L[C5?LC#WPMQ>^]$PMV0:>*&PV/>#B9G7@ST+VC?WG-W.SHO@ MW MY.TZKV5E*T7G4I/_".&ZA:)DWAHGY%X;='VNWCR'KJ;IK@K['\.@?YXDV M9^ZTMN<$]H8@]9^1EN=.I5VGTYX+<1Z52DMN:O71"UTM=.?"H&=A+EJPM M(Z'VB<\;F]?KK1MKLO&25'NB&UM>-;PPO.G5W^_X+'3+7GO[Q8.Y7TCP:&F6 M)5/+-\N*4=+/@N3K36>[]1@=H3\ZWG:V'[0K<.G[:&^?4N-H@%^Q3N^*R/UT M5+S"4?7OG;-^2=B\&GLR'V_N-,9CT>[7E%OK+M[#2_R7W\Q*71#\^13AUG>_MO)-/2NP^SNH%. MWM#+1A!F\ $&/![&'"KT9[+"KRHB>6C4O.;C19+HB7^ M&6?B=T68H@FU@)1&(U:51DJ#W=-,\IL3?G -<@<_]P$9=)?.*NP[V_O?#$@> M@$L?.F_Q;(G6]]7>HEK__-/0-8V1WWXI/>H;W&W$JTVQYILH^XHC7 M^>/*Q05SN'M]^.GX#QHG_/K#Y2^G!_\/4$L! A0#% @ #C *5T?*I#$J M P XPL !$ ( ! &QQ9&$M,C R,S X,3 N>'-D4$L! M A0#% @ #C *5Y6%@8'^"@ @(8 !4 ( !60, &QQ M9&$M,C R,S X,3!?;&%B+GAM;%!+ 0(4 Q0 ( XP"E<0M*?@5P< -57 M 5 " 8H. !L<61A+3(P,C,P.#$P7W!R92YX;6Q02P$" M% ,4 " ., I7^3Y&)S 2 B9 $@ @ $4%@ =&TR M,S(S,3@X9#%?.&LN:'1M4$L! A0#% @ #C *5[G"UE^O'P ;+T !8 M ( !="@ '1M,C,R,S$X.&0Q7V5X.3DM,2YH=&U02P4& / 4 !0!) 0 5T@ end